INTEGRAL MOLECULAR INC
Monoclonal antibody (MAb) therapeutic targeting Claudin 6 (CLDN6) for solid tumors
- Sector
- Biotech
- Headquarters
- Philadelphia, PA
- Total capital
- $51.9M
- Federal grants
- $18.1M
- 39 awards · 2014–2025
- Rank in peer group#201 of 514
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $33.8M
- 22 awards · Defense, Health and Human S, State
- Rank in Biotech#28 of 4373
- Granted patents
- 9
- 31 pending · first 2015
- Rank in peer group#35 of 514
Capital timeline
Latest events
- Federal contractHealth and Human S · Nichd: Service: Membrane Proteome Array Screening Service For Novel Monoclonal Antibody Target Identification$67K
- Federal grantHealth and Human S · Phase II · High-throughput Discovery of Antibodies against Understudied Membrane Proteins using mRNA$923K
- Federal grantHealth and Human S · Phase I · Development of Safe and Rapid Reporter Viruses for Studying Pathogenic and Pandemic Viruses$289K
- Federal contractHealth and Human S · Antibody Reagents For Immunologic Analysis Of Under-represented Mammalian Models$1.5M
- Federal contractHealth and Human S · To Discover And Characterize B Cell Epitopes Against The Viral Pathogens Rvfv, Cchfv, And EV-D68.$4.9M
- Federal contractState · U.S. Embassy Bangkok, Thailand. Laboratory Supplies.$61K
- Federal grantHealth and Human S · Phase I · Development of Safe and Rapid Reporter Viruses for Studying Pathogenic and Pandemic Viruses$289K
Show 54 earlier federal awards
- Federal grantHealth and Human S · Phase II · Development of Claudin MAbs for Treating Solid Tumors$395K
- Federal contractHealth and Human S · Membrane Proteome Array Service (ambis #2194825)$16K
- Federal contractHealth and Human S · SBIR Topic 118: Reagents For Immunologic Analysis Of Non-mammalian And Underrepresented Mammalian Models.$600K
- Federal contractState · Acquisition Of Arboviral Reporter Virus Particles On Behalf Of Afrims Thailand$44K
- Federal grantHealth and Human S · Phase II · Development of Claudin MAbs for Treating Solid Tumors$709K
- Federal grantHealth and Human S · Phase I · Identifying Regulators of Cellular Aging that can Prevent Alzheimer's Disease$89K
- Federal grantHealth and Human S · Phase I · High-throughput Discovery of Antibodies against Understudied Membrane Proteins$296K
- Federal contractHealth and Human S · Mpa+ind Screen$20K
- Federal contractHealth and Human S · Adjuvant Target Discovery For Vaccines And For Autoimmune And Allergic Diseases.$600K
- Federal grantHealth and Human S · Phase II · Next Generation Specificity Screening for Biotherapeutics using an Extracellular Proteome Array$204K
- Federal grantHealth and Human S · Phase II · Development of Claudin MAbs for Treating Solid Tumors$1.3M
- Federal grantHealth and Human S · Phase II · Development of Claudin MAbs for Treating Solid Tumors$600K
- Federal grantHealth and Human S · Phase I · Identifying Regulators of Cellular Aging that can Prevent Alzheimer's Disease$359K
- Federal contractState · Acquisition Of Reporter Virus Particles On Behalf Of Cdc, Thailand$42K
- Federal contractHealth and Human S · Lab Testing For Lipoparticle Delivery$17K
- Federal grantHealth and Human S · Phase II · Development of Kv1.3 Monoclonal Antibodies Targeting TEM Cells for Treating Autoimmune Disorders$589K
- Federal grantHealth and Human S · Phase I · Development of Nav1.7 Monoclonal Antibodies for Treating Pain$475K
- Federal grantHealth and Human S · Phase I · Development of Nav1.7 Monoclonal Antibodies for Treating Pain$475K
- Federal contractState · Medical Research Supplies-cdc Thailand (covid 19)$86K
- Federal grantHealth and Human S · Phase II · Next Generation Specificity Screening for Biotherapeutics using an Extracellular Proteome Array$502K
- Federal grantHealth and Human S · Phase II · Development of Kv1.3 Monoclonal Antibodies Targeting TEM Cells for Treating Autoimmune Disorders$634K
- Federal contractState · AFRIMS/0199-0107/VIRO/REAGENT For COVID19$34K
- Federal grantHealth and Human S · Phase II · Next Generation Specificity Screening for Biotherapeutics using an Extracellular Proteome Array$1.6M
- Federal grantHealth and Human S · Phase II · Next Generation Specificity Screening for Biotherapeutics using an Extracellular Proteome Array$934K
- Federal contractHealth and Human S · Covid Assay System$20K
- Federal grantHealth and Human S · Phase II · Development of CB1 Monoclonal Antibodies for Treating NASH$339K
- Federal grantHealth and Human S · Phase II · Development of Kv1.3 Monoclonal Antibodies Targeting TEM Cells for Treating Autoimmune Disorders$586K
- Federal contractHealth and Human S · B-cell Epitope Discovery And Mechanisms Of Antibody Protection$7.5M
- Federal grantHealth and Human S · Phase I · Identifying Agonist MAbs against GPCRs$132K
- Federal grantHealth and Human S · Phase II · Development of CB1 Monoclonal Antibodies for Treating NASH$697K
- Federal grantHealth and Human S · Phase I · Identifying New Immunomodulatory Targets for Alzheimers and Other Neurodegenerative Diseases$204K
- Federal grantHealth and Human S · Phase II · High-throughput Identification of Membrane Protein MAbs$262K
- Federal grantHealth and Human S · Phase II · Development of CB1 Monoclonal Antibodies for Treating NASH$438K
- Federal grantHealth and Human S · Phase I · Identifying New Immunomodulatory Targets for Alzheimers and Other Neurodegenerative Diseases$415K
- Federal grantHealth and Human S · Phase II · High-throughput Identification of Membrane Protein MAbs$100K
- Federal grantHealth and Human S · Phase I · Identifying New Immunomodulatory Targets for Alzheimers and Other Neurodegenerative Diseases$211K
- Federal grantHealth and Human S · Phase I · Identifying Agonist MAbs against GPCRs$355K
- Federal grantHealth and Human S · Phase I · Identifying Agonist MAbs against GPCRs$223K
- Federal grantHealth and Human S · Phase II · High-throughput Identification of Membrane Protein MAbs$525K
- Federal grantHealth and Human S · Phase II · High-throughput Identification of Membrane Protein MAbs$686K
- Federal grantHealth and Human S · Phase II · Development of P2X3 Ion Channel MAbs for the Treatment of Pain$215K
- Federal grantHealth and Human S · Phase II · Engineering of membrane protein chemosensors for therapeutic research$212K
- Federal grantHealth and Human S · Phase I · Development of High-expressing Ion Channels for Research and Therapeutic Applicat$208K
- Federal grantHealth and Human S · Phase II · Development of P2X3 Ion Channel MAbs for the Treatment of Pain$652K
- Federal grantHealth and Human S · Phase I · High-throughput Identification of Membrane Protein MAbs$225K
- Federal grantHealth and Human S · Phase I · High-throughput Identification of Membrane Protein MAbs$225K
- Federal grantHealth and Human S · Phase II · Engineering of membrane protein chemosensors for therapeutic research$492K
- Federal contractHealth and Human S · Igf::ot::igf B-cell Epitope Discovery And Mechanisms Of Antibody Protection$9M
- Federal contractHealth and Human S · TAS::75 0862::TAS Lipoparticles ( 5,000 Batch Units, CMG2 Receptor)-jsampson$8K
- Federal contractHealth and Human S · TAS::75 0862::TAS Integral Molecular-hopperlipoparticles: Quote # 0063010NIEHS$9K
- Federal contractHealth and Human S · Biomedical (basic)$150K
- Federal contractHealth and Human S · B Cell Epitope Research$9.1M
- Federal contractHealth and Human S · Requisition, Integral Molecular Inc., K. Tomer, Suraj Dhungana, Lipoparticles (5,000 Batch Units, CMG2 Receptor)$33K
- Federal contractDefense · Dengue Rvps$6K
Federal awards are summed by year (61 awards); hover a bar for the split. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#201 · top 39%
- Granted patents#35 · top 7%
- Linked publications#15 · top 3%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 9 granted of 40- GrantedCompositions And Methods Related To GPRC5D Binding Agents And Variants ThereofUSPTOUS 12,545,726
- GrantedClaudin 6 Antibodies And Uses ThereofUSPTOUS 12,497,450
- GrantedAntibodies Comprising A Common Light Chain And Uses ThereofUSPTOUS 12,428,474
Show all 40 patent records
- Compositions And Methods Related To GPRC5D Binding Agents And Variants ThereofFeb 10, 2026 · US 12,545,726Granted
- Claudin 6 Antibodies And Uses ThereofDec 16, 2025 · US 12,497,450Granted
- Antibodies Comprising A Common Light Chain And Uses ThereofSep 30, 2025 · US 12,428,474Granted
- Antibodies Directed To Claudin 6, Including Bispecific Formats ThereofMay 8, 2025 · Application 18740950Pending
- Claudin 6 Antibodies And Uses ThereofApr 24, 2025 · Application 18999081Pending
- Antibodies Directed To Claudin 6, Including Bispecific Formats ThereofJul 30, 2024 · US 12,049,502Granted
- Claudin 182 Antibodies, Methods Of Making The Same, And Uses ThereofDec 7, 2023 · Application 18327402Pending
- Glucose Transporter 4 Antibodies, Methods Of Making The Same, And Uses ThereofDec 5, 2023 · US 11,834,497Granted
- Methods And Compositions For Making Antibody Libraries And Antibodies Isolated From The SameNov 2, 2023 · Application 18041161Pending
- Antibodies Comprising A Common Light Chain And Uses ThereofFeb 22, 2022 · US 11,254,736Granted
- Claudin 6 Antibodies And Uses ThereofFeb 15, 2022 · US 11,248,046Granted
- Modified Ebolavirus Glycoproteins Comprising Mutations In The Head And Base Domains That Increase Antibody Cross-reactivityOct 5, 2021 · US 11,135,280Granted
- Lipoparticles Comprising Proteins, Methods Of Making, And Using The SameDec 15, 2015 · US 9,213,027Granted
- Claudin 18.2 Antibodies, Methods Of Making The Same, And Uses ThereofApplication 63347647Pending
- Methods And Compositions For Making Antibody Libraries And Antibodies Isolated From The SameApplication PCTUS2021045360Pending
- Methods and Compositions for Making Antibody Libraries and Antibodies Isolated From The SameApplication 63063647Pending
- Claudin 6 Antibodies And Uses ThereofApplication PCTUS2020018087Pending
- Antibodies Comprising A Common Light Chain And Uses ThereofApplication PCTUS2020018026Pending
- Glucose Transporter 4 Antibodies, Methods Of Making The Same, And Uses ThereofApplication PCTUS2019029809Pending
- Antibodies Comprising A Common Light Chain And Uses ThereofApplication 62806052Pending
- Claudin 6 Antibodies And Uses ThereofApplication 62806048Pending
- Glucose Transporter 4 Antibodies, Methods Of Making The Same, And Uses ThereofApplication 62664470Pending
- Pan Filovirus Vaccine Compositions And Methods Of MakingApplication PCTUS2017024320Pending
- Pan Filovirus Vaccine Compositions and Methods of MakingApplication 62423584Pending
- Pan Filovirus Vaccine Compositions and Methods of MakingApplication 62314009Pending
- Flaviviridae Proteins And Virions And Methods Of Use ThereofApplication PCTUS2016017522Pending
- Dengue Virions And Methods Of Use ThereofApplication 62116524Pending
- A Dengue Reporter Virus And Methods Of Making And Using The SameApplication PCTUS2007003660Pending
- Lipoparticles Comprising Ion Channels, Methods Of Making, And Using The SameApplication PCTUS2007002166Pending
- Reverse Transfection Of Cell Arrays For Structural And Functional Analyses Of ProteinsApplication PCTUS2005032537Pending
- Lipoparticles Comprising Proteins, Methods Of Making, And Using The SameApplication PCTUS2004024984Pending
- Antibodies And Compositions Against P2X Receptors And Uses ThereofApplication PCTUS2025042263Pending
- Antibodies Directed To Claudin 18.2, Including Bispecific Formats ThereofApplication 19594347Pending
- Antibodies Directed To Claudin 18.2, Including Bispecific Formats ThereofApplication PCTUS2024058961Pending
- Compositions And Methods Related To Chicken Recombinant Heavy-chain Only AntibodiesApplication PCTUS2024043196Pending
- Antibodies And Compositions Against P2X Receptors And Uses ThereofApplication 63683576Pending
- Antibodies Directed To Claudin 18.2, Including Bispecific Formats ThereofApplication 63606967Pending
- Antibodies Directed To Claudin 6, Including Bispecific Formats ThereofApplication PCTUS2023081599Pending
- Antibodies Directed To Claudin 6, Including Bispecific Formats ThereofApplication 63591924Pending
- Compositions And Methods Related To Chicken Recombinant Heavy-chain Only AntibodiesApplication 63520983Pending
Recent research by its founders
- Abstract 5535: GPRC5D multispecific antibodies: Engineering for affinity, cross-species reactivity, and bi/trispecific engagement in multiple myeloma20260 cites
- A Novel Antigenic Site Spanning Domains I and III of the Zika Virus Envelope Glycoprotein Is the Target of Strongly Neutralizing Human Monoclonal Antibodies20260 cites
- Anti-Ebola virus mAb 3A6 protects highly viremic animals from fatal outcome via binding GP(1,2) in a position elevated from the virion membrane20255 cites
Related companies, and why
- APTITUDE MEDICAL SYSTEMS INCSimilar federal contract value in Biotech · $36.5M in contracts
- AMGEN INCSimilar federal contract value in Biotech · $34.9M in contracts
- PLUS THERAPEUTICS, INC.Similar federal contract value in Biotech · $33.8M in contracts
- EvolvaSimilar federal contract value in Biotech · $30.3M in contracts
- HAWAII BIOTECH, INC.Similar federal contract value in Biotech · $27.6M in contracts
- SYNEDGEN, INC.Similar federal contract value in Biotech · $26.6M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .